Bellarose Nursing And Rehab | |
200 Bellarose Lake Way, Garner, North Carolina 27529 | |
(919) 985-8400 | |
Name | Bellarose Nursing And Rehab |
---|---|
Location | 200 Bellarose Lake Way, Garner, North Carolina |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 100 |
Occupancy Rate | 70.3% |
Medicare ID (CCN) | 345574 |
Legal Business Name | Bellarose Nursing And Rehab Center Inc |
Ownership Type | For Profit - Corporation |
NPI Number | 1093228397 |
Organization Name | BELLAROSE NURSING AND REHAB CENTER, INC. |
Address | 200 Bellarose Lake Way, Garner, NC 27529 |
Phone Number | 919-985-8400 |
News Archive
New research from the University of Bristol brings stem cell therapies for heart disease one step closer. The findings reveal that our bodies' ability to respond to an internal 'mayday' signal may hold the key to success for long-awaited regenerative medicine.
Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).
Newly published research shows that a screening program in the University of Cincinnati Medical Center Emergency Department helped detect an outbreak of HIV among persons who inject drugs in Hamilton County, Ohio, from 2014-18.
After a heart attack, the portions of the heart damaged by a lack of oxygen become scar tissue. Researchers have long sought ways to avoid this scarring, which can harden the walls of the heart, lessen its ability to pump blood throughout the body and eventually lead to heart failure. But new research from the University of North Carolina at Chapel Hill School of Medicine shows that interrupting this process can weaken heart function even further.
› Verified 6 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
New research from the University of Bristol brings stem cell therapies for heart disease one step closer. The findings reveal that our bodies' ability to respond to an internal 'mayday' signal may hold the key to success for long-awaited regenerative medicine.
Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).
Newly published research shows that a screening program in the University of Cincinnati Medical Center Emergency Department helped detect an outbreak of HIV among persons who inject drugs in Hamilton County, Ohio, from 2014-18.
After a heart attack, the portions of the heart damaged by a lack of oxygen become scar tissue. Researchers have long sought ways to avoid this scarring, which can harden the walls of the heart, lessen its ability to pump blood throughout the body and eventually lead to heart failure. But new research from the University of North Carolina at Chapel Hill School of Medicine shows that interrupting this process can weaken heart function even further.
› Verified 6 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 25.46 | 14.46 |
Percentage of long-stay residents who lose too much weight | 11.47 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 60.29 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.82 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.24 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0.41 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 1.92 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.62 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 21.12 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 92.25 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1.16 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 34.87 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 28.15 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 1.56 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
Percentage of short-stay residents who made improvements in function | 79.75 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 96.58 | 82.93 |
News Archive
New research from the University of Bristol brings stem cell therapies for heart disease one step closer. The findings reveal that our bodies' ability to respond to an internal 'mayday' signal may hold the key to success for long-awaited regenerative medicine.
Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).
Newly published research shows that a screening program in the University of Cincinnati Medical Center Emergency Department helped detect an outbreak of HIV among persons who inject drugs in Hamilton County, Ohio, from 2014-18.
After a heart attack, the portions of the heart damaged by a lack of oxygen become scar tissue. Researchers have long sought ways to avoid this scarring, which can harden the walls of the heart, lessen its ability to pump blood throughout the body and eventually lead to heart failure. But new research from the University of North Carolina at Chapel Hill School of Medicine shows that interrupting this process can weaken heart function even further.
› Verified 6 days ago
The Laurels Of Forest Glenn Location: 1101 Hartwell Street, Garner, North Carolina 27529 Phone: (919) 772-8888 | |
Bellarose Nursing And Rehab Location: 200 Bellarose Lake Way, Garner, North Carolina 27529 Phone: (919) 985-8400 |